Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

Last edition

News about "SK Bioscience"

SK Bioscience Begins Study of Sarbecovirus Vaccine

SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.

SK Bioscience | 30/01/2026 | By News Bureau

SK bioscience, MSD and Hilleman Advance Ebola Vaccine with CEPI Funding

he collaboration will receive up to USD 30 million in CEPI funding to support development of MSD’s Zaire ebolavirus vaccine, with a focus on improving manufacturing efficiency, enhancing thermostability and expanding affordable vaccine access in low- and middle-income countries.

SK Bioscience | 23/01/2026 | By News Bureau

SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine

SK bioscience's Phase 3 clinical trial of SKYVaricella aims to evaluate the immunogenicity and safety of the 2-shot varicella vaccine in roughly 800 children aged 12 months to 12 years, with completion targeted by 2027.

SK Bioscience | 02/09/2025 | By Dineshwori | 135

SK bioscience Submits IND Application for Phase 1/2 Trial of Adjuvanted Influenza Vaccine Candidate

SK bioscience has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety for Phase 1/2 clinical trials of its adjuvanted influenza vaccine candidate, NBP607B, aimed at boosting protection for older adults.

SK Bioscience | 19/07/2025 | By Mrinmoy Dey | 149

SK bioscience to Establish a Vaccine-Biopharma Hub

The R&PD center will be a 30,413.8 sq mt site in Songdo, Republic of Korea

SK Bioscience | 13/02/2023 | By Sudeep Soparkar | 599